Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8354642 | 0.89 | GPR119 (0.62) | GPR119KDM4ECYP2C19ALDH1A1L3MBTL1 | |
| SCHEMBL21876731 | 0.88 | GPR119 (0.59) | GPR119ALDH1A1L3MBTL1MAPTMEN1 | |
| SCHEMBL8352974 | 0.88 | GPR119 (0.59) | GPR119ALDH1A1L3MBTL1MAPTMEN1 | |
| SCHEMBL1458887 | 0.86 | GPR119 (0.76) | GPR119CYP2C19ALDH1A1MAPTMEN1 | |
| SCHEMBL8352146 | 0.86 | GPR119 (0.56) | GPR119KDM4ECYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL3486768 | 0.85 | GPR119 (1.00) | GPR119KDM4EALDH1A1MAPT | |
| SCHEMBL3704261 | 0.85 | GAA (0.57) | GPR119KDM4EALDH1A1MAPTTDP1 | |
| SCHEMBL7435316 | 0.84 | GPR119 (0.57) | GPR119ALDH1A1MAPT | |
| SCHEMBL8348627 | 0.84 | GPR119 (0.62) | GPR119CYP2C19ALDH1A1L3MBTL1MAPT | |
| SCHEMBL7318222 | 0.83 | GPR119 (0.55) | GPR119KDM4EALDH1A1MAPTHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772225-B2 | N-sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| US-7772225-B2 | N-sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| EP-1960359-A1 | NOVEL N-SULFAMOYL-PIPERIDINEAMIDES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS | Solvay Pharmaceuticals GmbH (DE) | 2008-08-27 | — | — | EP | disclosed |
| US-20070149512-A1 | N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH | 2007-06-28 | — | — | US | disclosed |
| US-20070149512-A1 | N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH | 2007-06-28 | — | — | US | disclosed |
| WO-2007065948-A1 | NOVEL N-SULFAMOYL-PIPERIDINEAMIDES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007065948-A1 | NOVEL N-SULFAMOYL-PIPERIDINEAMIDES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149512-A1 | N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | FABP4, GPR119, SRM | GPR119 2/4885KDM4E 1816/4885CYP2C9 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.